
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc is experiencing a positive outlook due to its compelling clinical results, particularly with the GRI-0621 program, which has demonstrated improvements in serum biomarkers related to fibrosis and positive lung function data without decline during its 12-week treatment period. The company's current valuation appears attractive, with significant upside potential highlighted by net present value (NPV) analyses that suggest a favorable investment opportunity. Additionally, the ongoing development of GRI-0803 as a novel oral agonist for autoimmune disorders further underlines GRI Bio's capacity to contribute innovative therapies in a market with high unmet needs.
Bears say
GRI Bio Inc reported a net loss of $3.4 million with an earnings per share (EPS) of $(1.28), which was worse than both internal estimates and market consensus, indicating potential financial instability. The company faces significant risks concerning liquidity and balance sheet management, compounded by the uncertain outcomes of clinical trials and the regulatory approval process for its product candidates, GRI-0621 and GRI-0803. Furthermore, the lengthy development and commercialization timelines for its therapies present ongoing challenges, overshadowing the substantial market potential estimated at approximately one billion dollars.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares